User:Bmhibbert/sandbox
Point-of-care genetic testing incorporates the newest most sophisticated techniques to identify variations in the genetic sequence at the bedside – enabling clinicians to react and alter therapy based upon the results.
Traditional genetic testing involves the analysis of chromosomes (DNA) in order to detect genotypes related to a heritable disease or phenotype of interest for clinical purposes. However, current testing methods require days to weeks before results are available limiting the clinical applicability of genetic testing in a number of circumstances.
Recently, the first point-of-care genetic test in medicine was demonstrated to be effective in identifying CYP2C19*2 carriers allowing tailoring of anti-platelet regimens to reduce high on treatment platelet reactivity [1]. Drs. Jason Roberts and Derek So from the [[University of Ottawa Heart Institute] collaborated with Spartan Biosciences [2] to validate a pharmacogenomics approach in patients undergoing percutaneous coronary intervention for acute coronary syndrome or stable coronary artery disease.